{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:21:53Z","timestamp":1788852113200,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejpb.2022.08.005","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T05:41:15Z","timestamp":1660714875000},"page":"140-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Modelling and simulation approaches to support formulation optimization, clinical development and regulatory assessment of the topically applied formulations \u2013 Nimesulide solution gel case study"],"prefix":"10.1016","volume":"178","author":[{"given":"Naresh","family":"Mittapelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.08.005_b0005","unstructured":"N.C.f.B.I. . PubChem Compound Summary for CID 4495, Nimesulide, in, 2021."},{"key":"10.1016\/j.ejpb.2022.08.005_b0010","unstructured":"I. Constantinescu, M. Florea, A. Nedelcu, C.-M. Monciu, C. Davila, Assay of nimesulide by ion association titration, in, 2009."},{"key":"10.1016\/j.ejpb.2022.08.005_b0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00003088-199835040-00001","article-title":"Clinical pharmacokinetics of nimesulide","volume":"35","author":"Bernareggi","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejpb.2022.08.005_b0020","unstructured":"U. FDA, TITLE 21--Food and drugs chapter i--food and drug administration department of health and human services subchapter D - drugs for human use, in."},{"key":"10.1016\/j.ejpb.2022.08.005_b0025","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40262-015-0292-0","article-title":"Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products","volume":"54","author":"Raney","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2022.08.005_b0030","unstructured":"CRCG, Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches, in: Vitrual Public workshop, CRCG, online, 2021."},{"issue":"8","key":"10.1016\/j.ejpb.2022.08.005_b0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ejpb.2022.08.005_b0040","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1208\/s12248-015-9819-4","article-title":"A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins","volume":"18","author":"Gill","year":"2016","journal-title":"The AAPS Journal"},{"issue":"3","key":"10.1016\/j.ejpb.2022.08.005_b0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40495-020-00212-x","article-title":"Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview","volume":"6","author":"Perry","year":"2020","journal-title":"Current Pharmacology Reports"},{"key":"10.1016\/j.ejpb.2022.08.005_b0050","first-page":"1049","article-title":"Physiologically Based Pharmacokinetic\/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms","volume":"12","author":"Loisios-Konstantinidis","year":"2020","journal-title":"Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen, Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.08.005_b0055","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1208\/s12248-020-00460-1","article-title":"Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents","volume":"22","author":"Pan","year":"2020","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.ejpb.2022.08.005_b0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","article-title":"Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy","volume":"47","author":"Abduljalil","year":"2020","journal-title":"J. Pharmacokinet Pharmacodyn."},{"key":"10.1016\/j.ejpb.2022.08.005_b0065","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.xphs.2021.02.016","article-title":"Development and Qualification of a Physiologically Based Pharmacokinetic Model of Finasteride and Minoxidil Following Scalp Application","volume":"110","author":"Ngampanya","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejpb.2022.08.005_b0070","doi-asserted-by":"crossref","first-page":"8589","DOI":"10.1038\/s41598-021-88154-2","article-title":"Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases","volume":"11","author":"Rasool","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejpb.2022.08.005_b0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpb.2020.08.005","article-title":"Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary","volume":"155","author":"Jamei","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.08.005_b0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpb.2019.07.011","article-title":"Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices","volume":"142","author":"Pepin","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.ejpb.2022.08.005_b0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10928-016-9492-y","article-title":"Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine","volume":"43","author":"Hartmanshenn","year":"2016","journal-title":"J. Pharmacokinet Pharmacodyn."},{"issue":"5","key":"10.1016\/j.ejpb.2022.08.005_b0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/psp4.12600","article-title":"Physiologically-based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1","volume":"10","author":"Tsakalozou","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.ejpb.2022.08.005_b0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/psp4.12421","article-title":"Current Scientific Considerations to Verify Physiologically-Based Pharmacokinetic Models and Their Implications for Locally Acting Products","volume":"8","author":"Zhao","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ejpb.2022.08.005_b0100","doi-asserted-by":"crossref","first-page":"105170","DOI":"10.1016\/j.ejps.2019.105170","article-title":"Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen","volume":"143","author":"Loisios-Konstantinidis","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.08.005_b0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.addr.2018.08.013","article-title":"Physiologically based pharmacokinetic modelling to guide drug delivery in older people","volume":"135","author":"Chetty","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.08.005_b0110","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejpb.2022.08.005_b0115","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1016\/j.bmc.2016.06.015","article-title":"Isomeric iodinated analogs of nimesulide: Synthesis, physicochemical characterization, cyclooxygenase-2 inhibitory activity, and transport across Caco-2 cells","volume":"24","author":"Yamamoto","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejpb.2022.08.005_b0120","unstructured":"Nimesulide, in."},{"key":"10.1016\/j.ejpb.2022.08.005_b0125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.5414\/CPP44270","article-title":"The diffusion of nimesulide gel into synovial fluid: a comparison between administration routes","volume":"44","author":"Erdogan","year":"2006","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1991","key":"10.1016\/j.ejpb.2022.08.005_b0130","first-page":"1071","article-title":"First dose and steady state pharmacokinetics of nimesulide and its 4-hydroxy metabolite in healthy volunteers","volume":"46","author":"Gandini","year":"1989","journal-title":"Farmaco (Societa chimica italiana"},{"key":"10.1016\/j.ejpb.2022.08.005_b0135","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2298\/VSP0512887J","article-title":"A pharmacokinetic comparison of three pharmaceutical formulations of nimesulide in healthy volunteers","volume":"62","author":"Jovanovi\u0107","year":"2005","journal-title":"Vojnosanit. Pregl."},{"issue":"10","key":"10.1016\/j.ejpb.2022.08.005_b0140","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/pharmaceutics12100942","article-title":"Physiologically Based Pharmacokinetic Modeling of Transdermal Selegiline and Its Metabolites for the Evaluation of Disposition Differences between Healthy and Special Populations","volume":"12","author":"Puttrevu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.08.005_b0145","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/jps.23155","article-title":"Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption","volume":"101","author":"Polak","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejpb.2022.08.005_b0150","doi-asserted-by":"crossref","unstructured":"E.G. Scheibel, Correspondence. Liquid Diffusivities. Viscosity of Gases, Industrial & Engineering Chemistry, 46 (1954) 2007-2008.","DOI":"10.1021\/ie50537a062"},{"key":"10.1016\/j.ejpb.2022.08.005_b0155","unstructured":"M.A. Polak S, Patel N, Combining machine learning and mechanistic modeling approaches to solve real life problems \u2013 assessment of the local tissue binding and its influence on the systemic exposure after topical application of drugs, in: ACoP9,October 6th \u2013 10th, 2018 San Diego, USA 2018."},{"key":"10.1016\/j.ejpb.2022.08.005_b0160","unstructured":"Nimesulide - Actions and Uses, Birkh\u00e4user Basel, 2005."},{"key":"10.1016\/j.ejpb.2022.08.005_b0165","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1081\/DDC-120002845","article-title":"Comparison of the transdermal absorption of nimesulide from three commercially available gel formulations","volume":"28","author":"Dayal","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2022.08.005_b0170","first-page":"516","article-title":"Ex vivo Skin Permeation Evaluation of An Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs","volume":"14","author":"Pereira","year":"2017","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.08.005_b0175","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s002280050510","article-title":"Analgesic efficacy and pharmacokinetics of topical nimesulide gel in healthy human volunteers: double-blind comparison with piroxicam, diclofenac and placebo","volume":"54","author":"Sengupta","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejpb.2022.08.005_b0180","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/acs.molpharmaceut.8b00176","article-title":"In Depth Analysis of Pressure-Sensitive Adhesive Patch-Assisted Delivery of Memantine and Donepezil Using Physiologically Based Pharmacokinetic Modeling and in Vitro\/in Vivo Correlations","volume":"15","author":"Mittapelly","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2022.08.005_b0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijpharm.2015.06.011","article-title":"A science based approach to topical drug classification system","volume":"491","author":"Shah","year":"2015","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.ejpb.2022.08.005_b0190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13555-016-0125-6","article-title":"Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients","volume":"6","author":"Lind","year":"2016","journal-title":"Dermatology and therapy"},{"key":"10.1016\/j.ejpb.2022.08.005_b0195","article-title":"Technical guidance for hazard analysis-emergency planning for extremely hazardous substances","author":"Epa","year":"1987","journal-title":"in"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122001710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122001710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:48:57Z","timestamp":1760546937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641122001710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":39,"alternative-id":["S0939641122001710"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.08.005","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling and simulation approaches to support formulation optimization, clinical development and regulatory assessment of the topically applied formulations \u2013 Nimesulide solution gel case study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}